Pancreatic Cancer Research

ResearcherMemorial Sloan Kettering Cancer CenterActive in the last 2 years

Marta Chiaravalli

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0009-0006-4159-2198; OpenAlex author ID A5067890923. Sources: OpenAlex.

Their work

Papers
11 (first author 4, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
57
Papers, trials and grants by year

2017: 2 papers · 2018: 3 papers · 2019: 1 paper · 2020: none · 2021: 1 paper · 2022: none · 2023: 1 paper · 2024: 2 papers · 2025: 1 paper

Papers 11

  1. Real-World Impact of Olaparib Exposure in Advanced Pancreatic Cancer Patients Harboring Germline BRCA1-2 Pathogenic Variants. Co-author DOI 10.1002/cam4.70364↗
  2. Germline pathogenic variants of cancer predisposition genes in a multicentre Italian cohort of pancreatic cancer patients. Co-author DOI 10.1016/j.ejca.2024.114226↗
  3. Comparison of first-line chemotherapy regimens in unresectable locally advanced or metastatic pancreatic cancer: a systematic review and Bayesian network meta-… First author DOI 10.1016/s1470-2045(24)00511-4↗
  4. Clinical and genomic characterization of pancreatic ductal adenocarcinoma patients with lung oligometastasis. First author DOI 10.1016/j.esmogo.2023.08.010↗
  5. Multidrug regimens for treatment of older patients with metastatic pancreatic cancer. First author DOI 10.1016/j.dld.2020.06.006↗
  6. Chemotherapy in elderly patients with pancreatic cancer: Efficacy, feasibility and future perspectives. First author DOI 10.1016/j.ctrv.2018.10.013↗
  7. A randomised phase 2 trial of nab-paclitaxel plus gemcitabine with or without capecitabine and cisplatin in locally advanced or borderline resectable pancreati… Co-author DOI 10.1016/j.ejca.2018.07.007↗
  8. Safety and efficacy of preoperative or postoperative chemotherapy for resectable pancreatic adenocarcinoma (PACT-15): a randomised, open-label, phase 2-3 trial. Co-author DOI 10.1016/s2468-1253(18)30081-5↗
  9. Nab-paclitaxel plus gemcitabine with or without capecitabine and cisplatin in metastatic pancreatic adenocarcinoma (PACT-19): a randomised phase 2 trial. Co-author DOI 10.1016/s2468-1253(18)30196-1↗
  10. Pancreatic ductal adenocarcinoma: State-of-the-art 2017 and new therapeutic strategies. Co-author DOI 10.1016/j.ctrv.2017.08.007↗
  11. Selecting patients for resection after primary chemotherapy for non-metastatic pancreatic adenocarcinoma. Co-author DOI 10.1093/annonc/mdx495↗

Closest collaborators

The 25 strongest of 57 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Michele Reni · 9 shared papers, 2017–2025 · strength 0.92
  2. Marina Macchini · 6 shared papers, 2018–2025 · strength 0.68
  3. Giampaolo Tortora · 4 shared papers, 2023–2025 · strength 0.65
  4. Lisa Salvatore · 3 shared papers, 2024–2025 · strength 0.50
  5. Luca Gianni · 6 shared papers, 2017–2021 · strength 0.49
  6. Silvia Matilde Zanon · 6 shared papers, 2017–2021 · strength 0.49
  7. Massimo Falconi · 5 shared papers, 2017–2024 · strength 0.41
  8. Umberto Peretti · 4 shared papers, 2018–2021 · strength 0.37
  9. Giulia Orsi · 2 shared papers, 2024–2025 · strength 0.32
  10. Guido Giordano · 2 shared papers, 2024–2025 · strength 0.32
  11. Stefano Cascinu · 2 shared papers, 2024–2025 · strength 0.32
  12. Claudio Doglioni · 4 shared papers, 2017–2018 · strength 0.26
  13. Gianpaolo Balzano · 4 shared papers, 2017–2018 · strength 0.26
  14. Stefania Mosconi · 2 shared papers, 2018–2025 · strength 0.23
  15. Paolo Giorgio Arcidiacono · 3 shared papers, 2017–2018 · strength 0.19
  16. Giulia Giordano · 1 shared paper, 2024 · strength 0.18
  17. Luca Mastrantoni · 1 shared paper, 2024 · strength 0.18
  18. Giovanni Trovato · 1 shared paper, 2024 · strength 0.18
  19. Mario Scartozzi · 1 shared paper, 2025 · strength 0.16
  20. Letizia Procaccio · 1 shared paper, 2025 · strength 0.16
  21. Andrea Spallanzani · 1 shared paper, 2025 · strength 0.16
  22. Elisa Giommoni · 1 shared paper, 2025 · strength 0.16
  23. Maria Grazia Rodriquenz · 1 shared paper, 2025 · strength 0.16
  24. Mariacristina Di Marco · 1 shared paper, 2025 · strength 0.16
  25. Alessandro Bittoni · 1 shared paper, 2025 · strength 0.16

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.